ScholarIQanswers from OpenAlex & ORCID
Manuel Cobo
ResearcherPublications, citations & collaboration network
Manuel Cobo is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Manuel Cobo have?
ScholarIQindexed works
Manuel Cobo has 546 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Manuel Cobo have?
ScholarIQcitation count
Manuel Cobo has 28,983 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Manuel Cobo?
ScholarIQh-index
Manuel Cobo has an h-index of 57 in OpenAlex.
What is the i10-index of Manuel Cobo?
ScholarIQi10-index
Manuel Cobo has an i10-index of 161 in OpenAlex.
What is the ORCID of Manuel Cobo?
ScholarIQorcid
The ORCID for Manuel Cobo is on the source record.
What is the OpenAlex record for Manuel Cobo?
ScholarIQopenalex
The OpenAlex for Manuel Cobo is on the source record.
What are the most-cited papers on Manuel Cobo?
ScholarIQmost cited works
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell, Enric Carcereny, Radj Gervais, A. Vergnenègre, Bartomeu Massutí, Enriqueta Felip, Ramón Palmero, Ramón García-Gómez, Cinta Pallarés, José Miguel Sánchez, Rut Porta, Manuel Cobo, Pilar Garrido, Flavia Longo, Teresa Morán, Amelia Insa, Filippo de Marinis, R. Corre, Isabel Bover, Alfonso Illiano, Éric Dansin, Javier de Castro, Michèle Milella, Noemı́ Reguart, Giuseppe Altavilla, Ulpiano Jiménez, Mariano Provencio, Miguel Ángel Moreno, Josefa Terrasa, José Muñoz-Langa, Javier Valdivia, Dolores Isla, Manuel Dómine, Olivier Molinier, Julien Mazières, Nathalie Baize, Rosario García‐Campelo, G. Robinet, Delvys Rodríguez‐Abreu, Guillermo López-Vivanco, Vittorio Gebbia, Lioba Ferrera-Delgado, P. Bombaron, Reyes Bernabé, Alessandra Bearz, Á. Artal, Enrico Cortesi, Christian Rolfo, María Sanchez-Ronco, Ana Drozdowskyj, Cristina Queralt, Itziar de Aguirre, José Luis Ramírez, José Javier Sánchez, Miguel Ángel Molina‐Vila, Miquel Tarón, Luis Paz‐Ares
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M. Gadgeel, Toyoaki Hida, Dariusz M. Kowalski, Manuel Cobo, Diego Cortinovis, Joseph W. Leach, Jonathan Polikoff, Carlos H. Barrios, Fairooz F. Kabbinavar, Osvaldo Arén Frontera, Filippo de Marinis, Hande Turna, Jong-Seok Lee, Marcus Ballinger, Marcin Kowanetz, Pei He, Daniel S. Chen, Alan Sandler, David R. Gandara
Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC
Suresh S. Ramalingam, Johan Vansteenkiste, David Planchard, Byoung Chul Cho, Jhanelle E. Gray, Yuichiro Ohe, Caicun Zhou, Thanyanan Reungwetwattana, Ying Cheng, Busyamas Chewaskulyong, Riyaz Shah, Manuel Cobo, Ki Hyeong Lee, Parneet Cheema, Marcello Tiseo, Thomas John, Meng‐Chih Lin, Fumio Imamura, Takayasu Kurata, Alexander Todd, Rachel Hodge, Matilde Saggese, Yuri Rukazenkov, Jean‐Charles Soria
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
Antonio Passaro, Jing Wang, Yan Wang, S.-H. Lee, Barbara Melosky, Jin‐Yuan Shih, Jing Wang, K. Azuma, Óscar Juan, Manuel Cobo, Enriqueta Felip, Nicolas Girard, Alexis B. Cortot, Raffaele Califano, Federico Cappuzzo, Scott Owen, Sanjay Popat, Ju Le Tan, Jorge Salinas, Pascale Tomasini, Ryan D. Gentzler, William N. William, Karen L. Reckamp, Toshiaki Takahashi, Sandip Ganguly, Dariusz M. Kowalski, Alessandra Bearz, Melanie Mackean, P. Barala, Ariel B. Bourla, Angela Girvin, James Greger, Dawn Millington, Monica Withelder, John Xie, Tao Sun, Shalin Shah, B. Diorio, Roland E. Knoblauch, Joshua Bauml, Rosario García Campelo, Byoung Chul Cho
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study
Myung‐Ju Ahn, Kentaro Tanaka, Luis Paz‐Ares, Robin Cornelissen, Nicolas Girard, Elvire Pons‐Tostivint, David Vicente Baz, Shunichi Sugawara, Manuel Cobo, M. Pérol, Céline Mascaux, Elena Poddubskaya, Satoru Kitazono, Hidetoshi Hayashi, Min Hee Hong, Enriqueta Felip, Richard D. Hall, Óscar Juan, Daniel Brungs, Shun Lü, Marina Chiara Garassino, Michael Chargualaf, Yong Zhang, Paul Howarth, Deise Uema, Aaron Lisberg, Jacob Sands, for the TROPION-Lung01 Trial Investigators, Gastón Lucas Martinengo, Juan Puig, Daniel Brungs, Bo Gao, Adnan Nagria, Christos S. Karapetis, Sagun Parakh, Cheol Park, Gaëtan Catala, Frédéric Forget, Sebahat Ocak, Naveen S. Basappa, Geoffrey Liu, Ines B. Menjak, Benjamin Shieh, Shun Lü, Feng Luo, Hongmei Sun, Jialei Wang, Yu Yao, Milada Zemanová, Jaafar Bennouna, Nicolas Girard, Laurent Greillier, Corinne Lamour, H. Léna, Céline Mascaux, Julien Mazières, Denis Moro‐Sibilot, M. Pérol, Elvire Pons‐Tostivint, Virginie Westeel, Akin Atmaca, Christine Greil, Niels Reinmuth, Christian Schumann, Thomas Wehler, Juergen Wolf, James Ho, Csaba Böcskei, Federico Cappuzzo, Filippo de Marinis, Claudia Proto, Manlio Mencoboni, Silvia Novello, Stefania Salvagni, Héctor Soto Parrà, Haruko Daga, Yasushi Goto, Hidetoshi Hayashi, Satoru Kitazono, Kiyotaka Yoh, Ryo Ko, Masashi Kondo, Toshiyuki Kozuki, Takayasu Kurata, Hideaki Mizutani, Kadoaki Ohashi, Satoshi Oizumi, Isamu Okamoto, Satoshi Sakaguchi, H Ozasa, Shunichi Sugawara, Yuichi Tambo, Motohiro Tamiya, Hiroshi Tanaka, Isamu Okamoto, Froylán López-López, Francisco Javier Ramírez Godinez, Jerónimo Rafael Rodríguez Cid, Robin Cornelissen, Steven Gans